Comparison of meropenem MICs and susceptibilities for carbapenemase- producing Klebsiella pneumoniae isolates by various testing methods

Journal of Clinical Microbiology

Volumn 48, Issue 7, 2010, Pages 2402-2406

  Bulik, Catharine C ^a   Fauntleroy, Kathy A ^b   Jenkins, Stephen G ^b   Abuali, Mayssa ^c   LaBombardi, Vincent J ^c   Nicolau, David P ^a   Kuti, Joseph L ^a  

^a HARTFORD HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEROPENEM; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEMASE; THIENAMYCIN DERIVATIVE;

ANALYTICAL ERROR; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CARBAPENEMASE PRODUCING KLEBSIELLA PNEUMONIAE; CONTROLLED STUDY; EPSILOMETER TEST; GENOTYPE; INTERMETHOD COMPARISON; KLEBSIELLA PNEUMONIAE; MICROSCAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SENSITITRE; VITEK 2; ANTIBIOTIC RESISTANCE; COMPARATIVE STUDY; DRUG EFFECTS; HUMAN; KLEBSIELLA INFECTION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES; SENSITIVITY AND SPECIFICITY;

KLEBSIELLA PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; SENSITIVITY AND SPECIFICITY; THIENAMYCINS;

EID: 77954447800     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00267-10     Document Type: Article

References (16)

1. Bratu, S., D. Landman, R. Haag, R. Recco, A. Eramo, M. Alam, and J. Quale. 2005. Rapid spread of carbapenem resistant Klebsiella pneumoniae in New York City. Arch. Intern. Med. 165:1430-1435.
2. Bratu, S., M. Mooty, S. Nichani, D. Landman, C. Gullans, B. Pettinato, U. Karumundi, P. Tolaney, and J. Quale. 2005. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob. Agents Chemother. 49:3018-3020.
3. Bulik, C. C., R. Quintiliani, J. S. Pope, J. L. Kuti, and D. P. Nicolau. Pharmacodynamics and tolerability of high-dose, prolonged infusion carbapenems in adults with cystic fibrosis: a review of 3 cases. Resp. Med. CME, in press. doi:10.1016/j.rmedc.2009.09.011.
4. Bulik, C. C., H. Christensen, P. Li, C. S. Sutherland, D. P. Nicolau, and J. L. Kuti. 2010. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 54:804-810.
5. Clinical Laboratory Standards Institute. 2008. Development of in vitro susceptibility testing criteria and quality control parameters, 8th ed. M23-A3. Clinical Laboratory Standards Institute, Wayne, PA.
6. Clinical Laboratory Standards Institute. 2008. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. M07-A8. Clinical Laboratory Standards Institute, Wayne, PA.
7. Clinical Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing: 19th informational supplement. M100-S19. Clinical Laboratory Standards Institute, Wayne, PA.
8. Clinical Laboratory Standards Institute. Accessed 18 January 2010. January 2010 meeting presentations: Enterobacteriaceae WG report. Clinical Laboratory Standards Institute, Wayne, PA. http://www.clsi.org/Content/ NavigationMenu/Committees/Microbiology/AST/January2010ASTMeetingPresentations/ EnterobacteriaceaeWGCarbapenemBreakpointDiscussionSlides.pdf.
9. Endimiani, A., A. M. Hujer, F. Perez, C. R. Bethel, K. M. Hujer, J. Kroeger, M. Oethinger, D. L. Paterson, M. D. Adams, M. R. Jacobs, D. J. Diekema, G. S. Hall, S. G. Jenkins, L. B. Rice, F. C. Tenover, and R. A. Bonomo. 2009. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the eastern U.S.A. J. Antimicrob. Chemother. 63:427-437.
10. Kuti, J. L., K. M. Moss, D. P. Nicolau, and R. F. Knauft. 2004. Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy. Pharmacotherapy 24:1641-1645.
11. Landman, D., S. Bratu, and J. Quale. 2009. Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniae. J. Med. Microbiol. 58:1303-1308.
12. Marchaim, D., S. Navon-Venzia, M. J. Schwaber, and Y. Carmeli. 2008. Isolation of imipenem-resistant Enterobacter species; emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob. Agents Chemother. 52:1413-1418.
13. Mauldin, P. D., C. D. Salgado, I. S. Hansen, D. T. Durup, and J. A. Bosso. 2010. Attributable hospital cost and length of stay associated with healthcare associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob. Agents Chemother. 54:109-115.
14. Nicasio, A. M., K. J. Eagye, D. P. Nicolau, E. Shore, M. Palter, J. Pepe, and J. L. Kuti. 2010. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J. Crit. Care 25:69-77.
15. Nordmann, P., G. Cuzon, and T. Naas. 2009. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9:228-236.
16. Quesada, M. D., M. Giménez, S. Molinos, G. Fernández, M. D. Sánchez, R. Rivelo, A. Ramirez, G. Banqué, and V. Ausina. 2010. Performance of VITEK 2 compact and overnight MicroScan panels for direct identification and susceptibility testing of Gram-negative bacilli from positive FAN BacT/ALERT blood culture bottles. Clin. Microbiol. Infect. 16:137-140.